PCSK9 as new target in hyperlipidemia treatment

Proprotein convertase subtilisin/kexin type 9 (PCSK 9) is a key regulator of cholesterol homeostasis acting via degradation of the low density lipoprotein (LDL) receptor. Loss of function PCSK 9 mutations result in very low LDL cholesterol serum levels and protection from cardiovascular disease wher...

Full description

Saved in:

Bibliographic Details
Published in:	Herz Vol. 39; no. 4; pp. 466 - 469
Main Authors:	Stawowy, P, Kelle, S, Fleck, E
Format:	Journal Article
Language:	English German
Published:	Germany 01-06-2014
Subjects:	Evidence-Based Medicine Humans Hyperlipidemias - drug therapy Hyperlipidemias - metabolism Hypolipidemic Agents - therapeutic use Molecular Targeted Therapy - methods Proprotein Convertase 9 Proprotein Convertases - antagonists & inhibitors Proprotein Convertases - metabolism Serine Endopeptidases - metabolism Serine Proteinase Inhibitors - therapeutic use Treatment Outcome
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Proprotein convertase subtilisin/kexin type 9 (PCSK 9) is a key regulator of cholesterol homeostasis acting via degradation of the low density lipoprotein (LDL) receptor. Loss of function PCSK 9 mutations result in very low LDL cholesterol serum levels and protection from cardiovascular disease whereas gain of function mutations increase serum LDL cholesterol. Based on in vitro and in vivo data antibodies targeting PCSK 9 have now emerged as a novel treatment option in patients with cardiovascular disease. This review briefly summarizes the biochemistry and function of PCSK9 and the results from recent phase II trials.
Bibliography:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23
ISSN:	0340-9937 1615-6692
DOI:	10.1007/s00059-013-3913-0